Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate.
In a previous study, we developed a novel mouse model for colitis-related carcinogenesis, utilizing a single dose of azoxymethane (AOM) followed by dextran sodium sulfate (DSS) in drinking water. In the present study, we investigated whether colonic neoplasms can be developed in mice initiated with a single injection of another genotoxic colonic carcinogen 1,2-dimethylhydrazine (DMH), instead of AOM and followed by exposure of DSS in drinking water. Male crj: CD-1 (ICR) mice were given a single intraperitoneal administration (10, 20 or 40 mg/kg body weight) of DMH and 1-week oral exposure (2% in drinking water) of a non-genotoxic carcinogen, DSS. All animals were killed at week 20, histological alterations and immunohistochemical expression of beta-catenin, cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS) were examined in induced colonic epithelial lesions (colonic dysplasias and neoplasms). Also, the beta-catenin gene mutations in paraffin-embedded colonic adenocarcinomas were analyzed by the single strand conformation polymorphism method, restriction enzyme fragment length polymorphism and direct sequencing. The incidences of colonic neoplasms with dysplastic lesions developed were 100% with 2.29+/-0.95 multiplicity, and 100% with 10.38+/-4.00 multiplicity in mice given DMH at doses of 10 mg/kg or 20 mg/kg and 2%DSS, respectively. Although approximately half of the mice given DMH at a dose of 40 mg/kg bodyweight were dead after 2-3 days after the injection, mice who received DMH 40 mg/kg and 2%DSS had 100% incidence of colonic neoplasms with 9.75+/-6.29 multiplicity. Immunohistochemical investigation revealed that adnocarcinomas, induced by DMH at all doses and 2%DSS, showed positive reactivities against beta-catenin, COX-2 and iNOS. In DMH/DSS-induced adenocarcinomas, 10 of 11 (90.9%) adenocacrcinomas had beta-catenin gene mutations. Half of the mutations were detected at codon 37 or 41, encoding serine and threonine that are direct targets for phosphorylation by glycogen synthase kinase-3beta. The present results suggests that, as in the previously reported model (AOM/DSS) our experimental protocol, DMH initiation followed by DSS, may provide a novel and useful mouse model for investigating inflammation-related colon carcinogenesis and for identifying xenobiotics with modifying effects.
Kohno
Hiroyuki
H
Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan. h-kohno@kanazawa-med.ac.jp
Suzuki
Rikako
R
Sugie
Shigeyuki
S
Tanaka
Takuji
T
D019813:1,2-Dimethylhydrazine; D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001397:Azoxymethane; D003092:Colitis / Q000139:chemically induced / Q000150:complications*; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000235:genetics* / Q000378:metabolism; D051546:Cyclooxygenase 2; D003598:Cytoskeletal Proteins / Q000235:genetics*; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D007249:Inflammation; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009154:Mutation; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics*; D051176:beta Catenin
C495267:CTNNB1 protein, mouse; D003598:Cytoskeletal Proteins; D015534:Trans-Activators; D051176:beta Catenin; D016264:Dextran Sulfate; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D019813:1,2-Dimethylhydrazine; D001397:Azoxymethane
Hum Pathol. 1983 Nov;14(11):931-68
6629368
Lab Invest. 1993 Aug;69(2):238-49
8350599
Br J Cancer. 2002 Apr 8;86(7):1124-9
11953860
Carcinogenesis. 2000 Nov;21(11):1935-40
11062151
J Gastroenterol Hepatol. 2002 Oct;17(10):1078-83
12201867
Cancer Res. 1998 Jan 15;58(2):334-41
9443414
Gastroenterology. 1990 Mar;98(3):694-702
1688816
J Pathol. 1994 Apr;172(4):313-6
8207611
Dig Dis Sci. 1985 Dec;30(12 Suppl):87S-102S
2998716
Genes Dev. 1996 Oct 15;10(20):2527-39
8895655
Cancer Sci. 2003 Nov;94(11):965-73
14611673
Science. 1998 Sep 4;281(5382):1509-12
9727977
Carcinogenesis. 2000 Apr;21(4):757-68
10753213
Carcinogenesis. 2005 Jan;26(1):229-38
15459021
Oncol Rep. 2004 May;11(5):951-6
15069531
J Biol Chem. 2004 Apr 30;279(18):18694-700
14976201
Cancer Sci. 2004 Jun;95(6):475-80
15182426
J Biol Chem. 1998 May 1;273(18):10823-6
9556553
Cancer Res. 1998 Mar 15;58(6):1130-4
9515795
Cancer Res. 1997 Apr 1;57(7):1233-7
9102204
Virchows Arch. 2002 Jul;441(1):1-11
12111194
Scand J Gastroenterol Suppl. 2002;(236):48-53
12408504
Science. 1997 Mar 21;275(5307):1787-90
9065402
Gut. 2001 Apr;48(4):526-35
11247898
Mol Carcinog. 1997 Jun;19(2):137-44
9210960
Adv Cancer Res. 1979;30:165-237
388992
Am J Surg Pathol. 1999 Aug;23(8):963-9
10435567
Cancer. 2000 Aug 15;89(4):733-40
10951334
Nature. 1999 Apr 1;398(6726):422-6
10201372
Lab Invest. 1974 Apr;30(4):505-13
4363166
Mod Pathol. 2001 Jan;14(1):29-39
11211307
Cancer Res. 1998 Jan 1;58(1):42-6
9426055
J Gastroenterol. 1998 Oct;33(5):618-24
9773924
Cancer Res. 1998 Mar 15;58(6):1127-9
9515794
Hum Mol Genet. 1992 Jul;1(4):229-33
1338904
Carcinogenesis. 2000 Jul;21(7):1319-27
10874009
Nature. 1992 Sep 17;359(6392):235-7
1528264
FASEB J. 2000 Jun;14(9):1188-201
10834941
Carcinogenesis. 2000 Jun;21(6):1117-20
10836998
J Biol Chem. 2001 Jun 8;276(23):20108-15
11274170
Inflammation. 1999 Apr;23(2):141-52
10213270
Hum Pathol. 1994 Nov;25(11):1160-71
7959660
Bioessays. 1999 Dec;21(12):1021-30
10580987
Cancer Res. 2003 Feb 1;63(3):728-34
12566320
Carcinogenesis. 2001 Nov;22(11):1885-90
11698353
Blood. 1990 Aug 15;76(4):655-63
2200535
Cancer Res. 2001 Nov 15;61(22):8085-8
11719432
Curr Opin Oncol. 1998 Jan;10(1):81-7
9466489
Cancer Sci. 2004 Sep;95(9):721-7
15471557
Nutr Cancer. 1984;6(2):92-7
6085849